Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636278 | 0.87 | EPOR (0.33) | TRPV1CYP26B1EPORCYP26A1NR1H4 | |
| SCHEMBL14693064 | 0.85 | HDAC4 (0.33) | TRPV1 | |
| SCHEMBL13636297 | 0.82 | EPOR (0.33) | TRPV1CYP26B1EPORCYP26A1NR1H4 | |
| SCHEMBL13636266 | 0.81 | EPOR (0.32) | TRPV1CYP26B1EPORCYP26A1NR1H4 | |
| SCHEMBL13636299 | 0.80 | EPOR (0.32) | TRPV1CYP26B1EPORNFE2L2MAOB | |
| SCHEMBL14692944 | 0.78 | RXRA (0.33) | TRPV1EPOR | |
| SCHEMBL13636289 | 0.77 | TRPV1 (0.35) | TRPV1CYP26B1EPORCYP26A1NR1H4 | |
| SCHEMBL13636279 | 0.72 | BCHE (0.35) | — | |
| SCHEMBL13636294 | 0.72 | TRPV1 (0.38) | TRPV1CYP26B1EPORCYP26A1NR1H4 | |
| SCHEMBL14692921 | 0.72 | HDAC4 (0.33) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304385-B2 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304385-B2 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | TRPV1 2679/4885CYP26B1 485/4885EPOR 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.